Ed Bowen is Vice President, AI & Machine Learning in R&D at GlaxoSmithKline (GSK). He leads a team of machine learning engineers using AI as a technology multiplier for GSK’s R&D strategy, enabling the discovery and development of transformational treatments for patients. His team delivers models and solutions across a wide range of medicines discovery problems including Target validation, enhanced clinical trial design, medicines scale-up, medicines portfolio optimization, protein engineering, and molecular design.
Ed participate or leads a number of industry initiatives, notably establishing a TransCelerate workstream sharing Placebo and Standard of Care clinical data across 17 companies for use in enhanced clinical trial design. The goal of the workstream is to gain a greater understanding of the placebo effect and apply practical applications of the data to accelerate medicines testing while reducing patient burden.
Ed holds an MA in Biology from Brown University, an MBA from Rensselaer Polytechnic Institute, a Master of Science in Electrical Engineering from the University of Rhode Island and a Bachelor of Science in Electrical Engineering from the US Coast Guard Academy. He is currently completing a PhD in Molecular Biology at the University of Miami.
Before working in Pharma R&D, Ed worked for Deloitte in their Quantitative Risk practice developing and implementing analytics solutions for a broad array of clients. Prior to that, he served multiple tours in the US Coast Guard as an electrical engineer implementing compute-intensive real-time signal processing solutions for global electronic navigation systems and as a shipboard deck watch officer. Ed was awarded several medals including the Armed Forces Expeditionary Medal and is a three-time recipient of the Humanitarian Service Medal for operations rescuing Haitian and Cuban migrants in the Caribbean.